The combination of tucatinib, trastuzumab, and capecitabine is the first systemic therapy to our knowledge to demonstrate clinically meaningful benefits, including prolongation of survival, in ...
Forty-eight patients with metastatic HRPC were registered. Forty-two patients were eligible, with a median age of 73 years and a median PSA level of 111 ng/mL; 78% had bone-only or bone and soft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results